Eyestem receives CDSCO approval Phase 2 trials of blindness treatment Eyecyte-RPE
The randomised, controlled phase 2 clinical trials will evaluate the safety and efficacy of Eyecyte-RPE in a larger group of subjects with moderate geographic atrophy (GA) and associated vision loss
Eyestem Research Pvt Ltd, a pioneering biotechnology company developing advanced scalable cell therapy solutions for blindness caused by dry age-related macular degeneration, has received approval from Central Drugs Standard Control Organisation (CDSCO) to initiate the clinical trial of its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE in India.
The randomised, controlled phase 2 clinical trials will evaluate the safety and efficacy of Eyecyte-RPE in a larger group of subjects with moderate geographic atrophy (GA) and associated vision loss.
